Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) C9 Antibodies:
anti-Mouse (Murine) C9 Antibodies:
anti-Human C9 Antibodies:
Go to our pre-filtered search.
Human Polyclonal C9 Primary Antibody for IHC (p), WB - ABIN657704
Rajaraman, Brenner, Neta, Pfeiffer, Wang, Yeager, Thomas, Fine, Linet, Rothman, Chanock, Inskip: Risk of meningioma and common variation in genes related to innate immunity. in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2010
Show all 3 references for ABIN657704
Human Polyclonal C9 Primary Antibody for ICC, IF - ABIN4299957
Neiman, Fredolini, Johansson, Lehtiö, Nygren, Uhlén, Nilsson, Schwenk: Selectivity analysis of single binder assays used in plasma protein profiling. in Proteomics 2013
Human Monoclonal C9 Primary Antibody for FACS, IA - ABIN4299956
Hatanaka, Seya, Yoden, Fukamoto, Semba, Inai: Analysis of C5b-8 binding sites in the C9 molecule using monoclonal antibodies: participation of two separate epitopes of C9 in C5b-8 binding. in Molecular immunology 1992
Serum-expressed apolipoprotein B-100 (show APOB Antibodies) protein, C9 Complement, and gelsolin (show GSN Antibodies) can be used for differential diagnosis of Barrertts esophagus and adenocarcinoma of esophagus.
Patients with advanced atrophic AMD (show AMD1 Antibodies) carried these rare variants more frequently than patients with neovascular AMD (show AMD1 Antibodies) (11 of 93 [11.8%] vs 40 of 835 [4.8%]; P = .04).
Data indicate that complement C9 binds to the ATPase (show DNAH8 Antibodies) domain of mortalin (show HSPA9 Antibodies).
Borrelial CspA binds the human terminal complement components C7 and C9 and blocks assembly and membrane insertion of the terminal complement complex (TCC (show SFXN1 Antibodies)).
Caveolin-1 (show CAV1 Antibodies) and dynamin-2 (show DNM2 Antibodies) are essential for removal of the complement C5b-9 complex via endocytosis.
the haploinsufficiency of C9, a terminal complement complex component, engenders reduced intraocular secretion of VEGF and decreased risk for CNV development.
It was concluded that variations in the complement component 9 gene are unlikely to influence clearance of chronic hepatitis B virus infection and hepatocellular carcinoma occurrence.
Mapping the intermedilysin-human CD59 (show CD59 Antibodies) receptor interface reveals a deep correspondence with the binding site on CD59 (show CD59 Antibodies) for complement binding proteins C8alpha and C9.
These results suggested that the lack of membrane attack complex because of an Arg95Stop mutation of the complement component 9 gene predisposed patients to pathognomonic glomerulonephritis.
Complement C5b-9 induce a JNK (show MAPK8 Antibodies)/Bid (show BID Antibodies)-dependent and JNK (show MAPK8 Antibodies)-independent necrotic cell death.
This gene encodes the final component of the complement system. It participates in the formation of the Membrane Attack Complex (MAC). The MAC assembles on bacterial membranes to form a pore, permitting disruption of bacterial membrane organization. Mutations in this gene cause component C9 deficiency.
complement component C9
, complement protein C9